Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …

Background Few large‐scale studies have been published using real‐world data related to
overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR) …

Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …

Introduction Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …

Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib, afatinib and osimertinib, are currently available for the management of EGFR …

Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …

Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …

Purpose An American Society of Clinical Oncology (ASCO) provisional clinical opinion
(PCO) offers timely clinical direction to ASCO's membership following publication or …

Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …

Background: Tyrosine kinase inhibitors (TKIs) are the standard of care for resectable and
metastatic non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor receptor …